Tislelizumab (Tevimbra) for Esophageal Cancer (online only)
Tislelizumab (Tevimbra) for Esophageal Cancer (online only)
May 13, 2024 (Issue: 1702)
The FDA has approved tislelizumab (Tevimbra –
BeiGene), a programmed death receptor-1 (PD-1)
blocking antibody, for treatment of unresectable
or metastatic esophageal squamous cell cancer in
adults who received prior systemic chemotherapy
that...more
- MA Shah et al. Treatment of locally advanced esophageal carcinoma: ASCO guideline. J Clin Oncol 2020; 38:2677. doi:10.1200/jco.20.00866
- HC Puhr et al. How we treat esophageal squamous cell carcinoma. ESMO Open 2023; 8:100789. doi:10.1016/j.esmoop.2023.100789
- L Shen et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study. J Clin Oncol 2022; 40:3065. doi:10.1200/jco.21.01926
- J Xu et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol 2023; 24:483. doi:10.1016/s1470-2045(23)00108-0
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Tislelizumab (Tevimbra) for Esophageal Cancer (online only)
Article code: 1702h
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.